



PRESS RELEASE
**PUBLICATION OF AN INFORMATION DOCUMENT IN RESPECT OF A
TRANSACTION OF MAJOR SIGNIFICANCE WITH A RELATED PARTY**

Capua, 28 October 2015 – Pierrel S.p.A. (the “**Company**”) discloses that – pursuant to Article 5 of the Regulations on Transactions with Related Parties adopted by the Consob in its decision no. 17221 of 12 March 2010, as subsequently revised and updated, as well as paragraph 9.1.6 of the Procedure regarding the rules on transactions with parties related to the Company – today published the information document summarising the terms and conditions of the convertible bonds for a maximum of CHF 3.3 million (approximately € 3.0 million) by THERAMetrics holding AG, a company within the Pierrel Group, whose issue was already communicated to the market by the Company on 16 and 21 October 2015, where the first tranche will be subscribed, among others, by Fin Posillipo S.p.A., a related party to the Company as the principal shareholder of the Company with a shareholding in the relative share capital of some 36.4% and as Raffaele Petrone, Chairman of the Board of Directors of the Company, is also the CEO and relevant shareholder in Fin Posillipo S.p.A..

The information document is available to the public at the registered office of the Company and at Borsa Italiana S.p.A., as well as on the web site of the Company at www.pierrelgroup.com, section *Investor Relations/Corporate Governance/Related Parties*, and on the authorised storage mechanism Nis-Storage (www.emarketstorage.com).

Pierrel S.p.A. is a global supplier to the pharmaceutical, biopharmaceutical and life science industries, specialising in the discovery of medicinal product candidates and the repositioning of existing drugs for new therapeutic indications and clinical research (TCRDO Division), pharmaceutical production (Contract Manufacturing Division) and the development, registration and licensing of new drugs and medical devices (Pharma Division). Pierrel Group is listed on the MTA exchange which is organised and managed by Borsa Italiana and boasts over 60 years’ experience in the pharmaceutical sector, being one of Europe’s leading producers of local and dental anaesthetics. The TCRDO Division, working across Europe and the US, is recognised internationally for its research and development into tech based clinical research innovations with its Drug Repositioning and Repurposing System (“DRR2.0”) and Integrated Clinical Development Services (“ICDS”) for the pharmaceutical, biotechnology and biomedical industries. The parent company of the TCRDO Division (**THERAMetrics holding AG**, listed in the Swiss stock exchange) holds the innovative interactive **DRR2.0** platform, which runs on a database of 24 million scientific publications (being virtually all of those available in the field of biomedical literature), of over 4,900 drugs and of 9,400 illnesses. With this data, never before collected in one place and stored in the cloud, the Search and Match algorithm can show a researcher not only the candidate drug but also a detailed road map with indications of possible second medical uses. The database can be searched by molecule or by illness. Pierrel also has a production unit in Capua, close to Naples, Italy, that has been authorised by the European Medicines Agency (EMA) and the Food and Drug Administration (FDA) for the aseptic production of injectable medicines. The subsidiary Pierrel Pharma S.r.l. has registered and distributes the Orabloc® dental anaesthetic in Canada, US, Russia and Europe. The registered office of Pierrel S.p.A. is in Capua (CE), Italy.



For further information:

Pierrel S.p.A.

Investor Relations

Raffaele Petrone

E-mail:

investor.relations@pierrelgroup.com

tel. +39 0823 626 111

fax +39 0823 626 228

Global Consult s.r.l.

Media Relations

Rossana Del Forno

E-mail: areacomunicazione@globalconsultsrl.com

tel. +39 333 6178665